Sarepta Therapeutics, Inc. (NASDAQ: SRPT) announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Advisory ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Sarepta Therapeutics (SRPT) Continues Grind Higher from Morning LowsApril 26, 2016 12:45 PM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightApril 26, 2016 7:28 AM Despite Negative FDA Panel, Needham & Company Sees Approval of Sarepta's (SRPT) Eteplirsen as Early as Next YearApril 26, 2016 7:23 AM Sarepta Therapeutic (SRPT) PT Cut to $5 at RBC CapitalApril 26, 2016 7:14 AM Sarepta Therapeutics (SRPT) Resumes Trading; Shares down 53%April 26, 2016 7:11 AM Sarepta Therapeutics (SRPT) to resume trading at 7:10AM ETApril 26, 2016 7:07 AM Sarepta Therapeutic (SRPT) PT Cut to $7 at Jefferies Following Negative AdComApril 26, 2016 6:49 AM Oppenheimer Downgrades Sarepta Therapeutic (SRPT) to PerformApril 26, 2016 6:40 AM Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular DystrophyApril 25, 2016 10:58 PM FDA Panel 6 YES, 7 NO That Eteplirsen Shows Clinical Benefit (SRPT)April 25, 2016 6:12 PM FDA Panel Starts Getting Cautious on Sarepta's (SRPT) EteplirsenApril 25, 2016 12:19 PM Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdComApril 25, 2016 7:02 AM